Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients
Abstract Aim Soluble suppression of tumorigenicity‐2 (sST2) is a strong prognostic biomarker in heart failure. The emerging understanding of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may provide insight into mechanistic aspects of the d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.12673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544441773064192 |
|---|---|
| author | Sandra Crnko Markella I. Printezi Tijn P.J. Jansen Laurynas Leiteris Manon G. van derMeer Hilde Schutte Martijn vanFaassen Bastiaan C. duPré Nicolaas deJonge Folkert W. Asselbergs Carlo A.J.M. Gaillard Hans Kemperman Pieter A. Doevendans Joost P.G. Sluijter Linda W. vanLaake |
| author_facet | Sandra Crnko Markella I. Printezi Tijn P.J. Jansen Laurynas Leiteris Manon G. van derMeer Hilde Schutte Martijn vanFaassen Bastiaan C. duPré Nicolaas deJonge Folkert W. Asselbergs Carlo A.J.M. Gaillard Hans Kemperman Pieter A. Doevendans Joost P.G. Sluijter Linda W. vanLaake |
| author_sort | Sandra Crnko |
| collection | DOAJ |
| description | Abstract Aim Soluble suppression of tumorigenicity‐2 (sST2) is a strong prognostic biomarker in heart failure. The emerging understanding of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may provide insight into mechanistic aspects of the disease–biomarker interaction. So far, it is unknown whether sST2 exhibits a diurnal rhythm. Repeated measurements of sST2 may aid in clinical decision making. The goal of this study was to investigate whether sST2 exhibits diurnal variation in patients with heart failure with reduced ejection fraction (HFrEF) and in control subjects, thereby enhancing its diagnostic and prognostic values. Methods and results The study comprised 32 subjects: 16 HFrEF patients and 16 controls. Blood was collected at seven subsequent time points during a 24 h time period. sST2, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), melatonin, and cortisol were measured from serum. Peak values of sST2 clustered at daytime (modal value: 5 p.m.) in 87.6% of all subjects (81.3% of patients, P = 0.021; 93.8% of controls, P = 0.001), and minimum concentrations at night‐time (modal value: 5 a.m.) in 84.4% (87.5% of patients, P = 0.004 81.3% of controls, P = 0.021). A cosinor analysis of mean normalized sST2 values revealed significant cosine shaped 24 h oscillations of patients (P = 0.026) and controls (P = 0.037). NT‐proBNP in contrast did not show a diurnal rhythm, while melatonin and cortisol patterns were intact in all subjects. Conclusions sST2 exhibits a diurnal rhythm with lower values in the morning than in the late afternoon. This new insight could lead to refinement of its diagnostic and prognostic values through specified and consistent sampling times with repeated measurements. For example, by measuring sST2 during the afternoon, when levels are at their highest, false negatives on prognosis prediction could be avoided. |
| format | Article |
| id | doaj-art-e41b91a2d1e04fdcb188245108b36523 |
| institution | Kabale University |
| issn | 2055-5822 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-e41b91a2d1e04fdcb188245108b365232025-02-03T10:25:46ZengWileyESC Heart Failure2055-58222020-06-01731224123310.1002/ehf2.12673Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patientsSandra Crnko0Markella I. Printezi1Tijn P.J. Jansen2Laurynas Leiteris3Manon G. van derMeer4Hilde Schutte5Martijn vanFaassen6Bastiaan C. duPré7Nicolaas deJonge8Folkert W. Asselbergs9Carlo A.J.M. Gaillard10Hans Kemperman11Pieter A. Doevendans12Joost P.G. Sluijter13Linda W. vanLaake14Department of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsRegenerative Medicine Centre University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Laboratory Medicine University Medical Centre Groningen, University of Groningen Groningen The NetherlandsDivision of Internal Medicine Erasmus Medical Centre Rotterdam The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDivision of Internal Medicine and Dermatology University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Clinical Chemistry and Haematology University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsDepartment of Cardiology, Experimental Cardiology Laboratory University Medical Centre Utrecht Utrecht The NetherlandsAbstract Aim Soluble suppression of tumorigenicity‐2 (sST2) is a strong prognostic biomarker in heart failure. The emerging understanding of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may provide insight into mechanistic aspects of the disease–biomarker interaction. So far, it is unknown whether sST2 exhibits a diurnal rhythm. Repeated measurements of sST2 may aid in clinical decision making. The goal of this study was to investigate whether sST2 exhibits diurnal variation in patients with heart failure with reduced ejection fraction (HFrEF) and in control subjects, thereby enhancing its diagnostic and prognostic values. Methods and results The study comprised 32 subjects: 16 HFrEF patients and 16 controls. Blood was collected at seven subsequent time points during a 24 h time period. sST2, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), melatonin, and cortisol were measured from serum. Peak values of sST2 clustered at daytime (modal value: 5 p.m.) in 87.6% of all subjects (81.3% of patients, P = 0.021; 93.8% of controls, P = 0.001), and minimum concentrations at night‐time (modal value: 5 a.m.) in 84.4% (87.5% of patients, P = 0.004 81.3% of controls, P = 0.021). A cosinor analysis of mean normalized sST2 values revealed significant cosine shaped 24 h oscillations of patients (P = 0.026) and controls (P = 0.037). NT‐proBNP in contrast did not show a diurnal rhythm, while melatonin and cortisol patterns were intact in all subjects. Conclusions sST2 exhibits a diurnal rhythm with lower values in the morning than in the late afternoon. This new insight could lead to refinement of its diagnostic and prognostic values through specified and consistent sampling times with repeated measurements. For example, by measuring sST2 during the afternoon, when levels are at their highest, false negatives on prognosis prediction could be avoided.https://doi.org/10.1002/ehf2.12673Circadian rhythmDiurnal rhythmHeart failureBiomarkersST2NT‐proBNP |
| spellingShingle | Sandra Crnko Markella I. Printezi Tijn P.J. Jansen Laurynas Leiteris Manon G. van derMeer Hilde Schutte Martijn vanFaassen Bastiaan C. duPré Nicolaas deJonge Folkert W. Asselbergs Carlo A.J.M. Gaillard Hans Kemperman Pieter A. Doevendans Joost P.G. Sluijter Linda W. vanLaake Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients ESC Heart Failure Circadian rhythm Diurnal rhythm Heart failure Biomarker sST2 NT‐proBNP |
| title | Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients |
| title_full | Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients |
| title_fullStr | Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients |
| title_full_unstemmed | Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients |
| title_short | Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients |
| title_sort | prognostic biomarker soluble st2 exhibits diurnal variation in chronic heart failure patients |
| topic | Circadian rhythm Diurnal rhythm Heart failure Biomarker sST2 NT‐proBNP |
| url | https://doi.org/10.1002/ehf2.12673 |
| work_keys_str_mv | AT sandracrnko prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT markellaiprintezi prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT tijnpjjansen prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT laurynasleiteris prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT manongvandermeer prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT hildeschutte prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT martijnvanfaassen prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT bastiaancdupre prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT nicolaasdejonge prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT folkertwasselbergs prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT carloajmgaillard prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT hanskemperman prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT pieteradoevendans prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT joostpgsluijter prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients AT lindawvanlaake prognosticbiomarkersolublest2exhibitsdiurnalvariationinchronicheartfailurepatients |